Medicare Benefits Schedule - Note IN.4.4

Item 61644 was introduced as a direct substitute for MBS item 61325. It may only be used during specified time periods, following a valid request for a single rest myocardial perfusion study to which item 61325 would apply but cannot be performed due to unavailability of thallium-201 (Tl-201).

Item 61644 was introduced via the Health Insurance (Section 3C Diagnostic Imaging – Additional Nuclear Medicine Services) Determination 2022. This is available on the Federal Register of Legislation.

Item 61644 is available for the period from 1 April 2022 until 30 June 2023. If the supply of Tl-201 is re-established before 30 June 2023, the substitute item may be suspended early to reflect this. Alternatively, the date may be extended if necessary.

Related Items: 61644

• Previous - Note IN.4.3
• Next - Note IN.4.5

Bulk bill incentive

Single rest myocardial perfusion study for the assessment of the extent and severity of non‑viable myocardium, with PET, if:

(a) the service is performed because the service to which item 61325 applies cannot be performed due to unavailability of thallous chloride 201 (Tl-201); and

(b) the patient has left ventricular systolic dysfunction and probable or confirmed coronary artery disease; and

(c) the service is performed in conjunction with a rest myocardial perfusion study using technetium-99m; and

(d) the service is requested by a specialist or a consultant physician; and

(e) the service is not associated with a service to which item 11704, 11705, 11707, 11714, 11729 or 11730 applies; and

(f) this service and item 61325 are applicable only twice each 24 months (R)

Item 61644 is a substitute item that may only be used during periods of national shortage of Tl-201. See IN.4.4 of explanatory notes to this Category for further information. 

Fee: $329.00 Benefit: 75% = $246.75 85% = $279.65

(See para IN.4.4, IR.4.2 of explanatory notes to this Category)